Industry9 min read
Generic Semaglutide: Live Abroad, US Locked Till 2031
Semaglutide generics launched in India and Canada in 2026 at $14-78 a month. US patents run to December 2031. What US buyers can source now.
Peptide Industry News
Brand launches, primer pieces, broader coverage.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Industry News
Industry12 min read
GLP-1 Bone Loss: What the 5-Year Data Actually Shows
Five-year records on 73,483 GLP-1 users show higher osteoporosis rates — but only in some groups. The numbers, the mechanism, what people track.
Industry7 min read
HM17321: Roche's $2.3B Muscle-Sparing Obesity Peptide
Roche paid $190M upfront for HM17321, a urocortin-2 analog that raised lean mass while cutting fat in monkeys. What it changes for GLP-1 users now.
Industry9 min read
Can You Mix Peptides in the Same Syringe?
Which peptide pairs get combined in one syringe, which never are, and why pre-blended vials sidestep the question. Sorted by pH, stability and sterility.
Industry6 min read
Yale Study: Semaglutide Needs Hunger Neurons for Fat Loss
A PNAS study found semaglutide switches ON AgRP hunger neurons — and disrupting them blunts fat loss. Why returning appetite isn't the same as failure.
Industry7 min read
Retatrutide Early Access: Who Actually Qualifies
Lilly opened retatrutide early access before FDA approval. Four criteria gate it, three parties sign off — and why almost nobody gets through.
Industry7 min read
Hims Peptide Launch: What Ships, What Waits on FDA
Hims & Hers will sell sermorelin, glutathione and NAD+ by year-end. BPC-157 and five more wait on FDA rulemaking — the timeline, and where they sell now.
Industry11 min read
GLP-1s and Birth Control: What the Labels Require
Tirzepatide cut oral contraceptive exposure 20%; semaglutide showed none. New Aug 2026 consensus guidelines. Which compounds carry the warning.
Industry10 min read
Is Retatrutide a Biologic? The FDA Fight Explained
A court sent FDA back to the drawing board on retatrutide's classification. The 41st amino acid decides whether it can ever be compounded.
Industry9 min read
Lilly Sues 6 Retatrutide Sellers: Who's Affected
Eli Lilly filed six suits on August 12 over retatrutide sales. The named defendants, the payment-processor ask, and what actually changes for buyers.
Industry9 min read
GLP-1 Antitrust Suit Tossed: What Changes for Buyers
A Texas judge dismissed Strive's antitrust case against Lilly and Novo, ruling compounded GLP-1s never competed with the branded drugs at all.
Industry5 min read
Peptide Vendor Code Names Decoded: GLP-3, MHC-3 RT & More
GLP-3 RT, ION-3R, EZP-3P and R-30 are the same compound. A decoder for every obfuscated vendor SKU, and what each one actually costs per mg.
Industry5 min read
How to Verify a Peptide COA: 6 Checks
A vendor founder went to prison for forging lab certificates. Six checks that separate a real Certificate of Analysis from a PDF that proves nothing.
Industry8 min read
Compounded GLP-1 State Laws: Who Restricts What
California codified a stricter copy rule, Ohio suspended 30+ licenses, Washington issued stop-service orders. The state layer now gates compounded GLP-1s.
Industry7 min read
CagriSema vs Tirzepatide: REIMAGINE 4 Diabetes Data
Novo's amylin/GLP-1 combo matched tirzepatide on weight but missed on blood sugar in the 68-week REIMAGINE 4 head-to-head. What it means for buyers.
Industry7 min read
Pfizer Kills Oral GLP-1 Peptide: What's Left in Pipeline
Pfizer axed its ex-Metsera oral GLP-1 peptide and a phase 2 GIPR antagonist. What survived the cut, and what it changes for research-peptide sourcing.
Industry7 min read
What Doctors Think About Peptides: New Survey Data
48% of physicians say patients disclosed peptide use last year — and 84% got their information from influencers, not doctors. The full survey data.
Industry7 min read
Novo Sues Lilly Over GLP-1 Ads: The Dose Mismatch
Novo asked a court to halt Lilly's GLP-1 ads for pitting max-dose tirzepatide against outdated semaglutide doses. What the trial data actually shows.